Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinryze pediatric acute hereditary angioedema dose-response study
2011-000369-11Phase 2Completed
- Sponsor
- ViroPharma Incorporated
- Start
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of c1-esterase inhibitor in hereditary angioedema (HAE) (2 arms), sponsored by ViroPharma Incorporated. Primary endpoint: Unequivocal beginning of relief of the defining symptom within 4 hours. Started Mar 2011; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2011-000369-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000369-11.